Increased susceptibility to infections is among the main safety concerns raised by anti-TNF-α agents. We describe two cases of cutaneous actinomycosis in patients undergoing anti-TNF-α therapy: a 49-year-old female treated with etanercept for rheumatoid arthritis and a 57-year-old female treated with infliximab for psoriasis. Both patients had discharge with the intermittent presence of sulfur granules occurring at the site of previous surgical wounds. Bacteriological culture demonstrated Actinomyces. Since in both cases laboratory findings and medical imaging ruled out visceral actinomycosis, oral antibiotics were introduced without discontinuing anti-TNF-α. The first patient did not relapse after 2 years. The second one did and received a second course of antibiotics combined with transient interruption of the anti-TNF-α therapy. The risk of developing actinomycosis is reported to be similar in immunocompetent and immunocompromised patients, however cases of cutaneous actinomycosis occurring during anti-TNF-α therapy need to be recognized and may be under-reported.

Keywords:
Actinomycosis, Infliximab, Etanercept
1.
Crum NF, Lederman ER, Wallace MR: Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302.
2.
Marie I, Lahaxe L, Levesque H, Heliot P: Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab. QJM 2008;101:419-421.
3.
Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM: Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax 2007;62:1013-1014.
4.
Thimmapuram J, Oosterveen S: Actinomyces osteomyelitis of the mandible complicating infliximab and azathioprine therapy for Crohn's disease. Am J Gastroenterol 2011;106:357.
5.
Raymond A, Smego J, Ginamarte F: Actinomycosis. Clin Infect Dis 1998;26:1255-1261.
6.
Patil D, Siddaramappa B, Manjunathswamy BS, Pandit AM, Dastikop S, Fernandes C, Kutre S, Angolkar M: Primary cutaneous actinomycosis. Int J Dermatol 2008;47:1271-1273.
7.
Reichenbach J, Lopatin U, Mahlaoui N, Beovic B, Siler U, Zbinden R, Seger RA, Galmiche L, Brousse N, Kayal S, Güngör T, Blanche S, Holland SM: Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009;49:1703-1710.
8.
Mansouri P, Farshi S, Khosravi A, Naraghi ZS: Primary cutaneous actinomycosis caused by Actinomyces bovis in a patient with common variable immunodeficiency. J Dermatol 2011;38:911-915.
9.
Tubach F, Salmon-Céron D, Ravaud P, Mariette X; RATIO Study Group: The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 2005;72:456-460.
10.
Hansen RA, Gartlehner G, Powell GE, Sandler RS: Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007;5:729-735.
11.
Von Graevenitz A: Actinomyces neuii: review of an unusual infectious agent. Infection 2011;39:97-100.
12.
Gomes J, Pereira T, Carvalho A, Brito C: Primary cutaneous actinomycosis caused by Actinomyces meyeri as first manifestation of HIV infection. Dermatol Online J 2011;17:5.
13.
Murchan EM, Redelman-Sidi G, Patel M, Dimaio C, Seo SK: Esophageal actinomycosis in a fifty-three-year-old man with HIV: case report and review of the literature. AIDS Patient Care STDS 2010;24:73-78.
14.
Takeda H, Mitsuhashi Y, Kondo S: Cutaneous disseminated actinomycosis in a patient with acute lymphocytic leukemia. J Dermatol 1998;25:37-40.
15.
Bassiri AG, Girgis RE, Theodore J: Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart-lung transplant recipients and a review of the literature. Chest 1996;109:1109-1111.
16.
Che Y, Tanioka M, Matsumura Y, Kore-Eda S, Miyachi Y: Primary cutaneous actinomycosis on the nose. Eur J Dermatol 2007;17:167-168.
17.
Hoppé E, Masson C, Audran M, Drillon M, Andreu M, Saraux A, Berthelot JM, Maugars Y, Hmamouchi I, Morel J: Whipple's disease diagnosed during biological treatment for joint disease. Joint Bone Spine 2010;77:335-339.
18.
Kneitz C, Suerbaum S, Beer M, Müller J, Jahns R, Tony HP: Exacerbation of Whipple's disease associated with infliximab treatment. Scand J Rheumatol 2005;34:148-151.
19.
Zautner AE, Schmitz S, Aepinus C, Schmialek A, Podbielski A: Subcutaneous fistulae in a patient with femoral hypoplasia due to Actinomyces europaeus and Actinomyces turicensis. Infection 2009;37:289-291.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.